nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC6A3—Gilles de la Tourette syndrome	0.498	0.573	CbGaD
Amphetamine—DRD2—Gilles de la Tourette syndrome	0.37	0.426	CbGaD
Amphetamine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00691	0.123	CbGeAlD
Amphetamine—CARTPT—nervous system—Gilles de la Tourette syndrome	0.00422	0.0749	CbGeAlD
Amphetamine—TAAR1—nervous system—Gilles de la Tourette syndrome	0.00422	0.0749	CbGeAlD
Amphetamine—TAAR1—central nervous system—Gilles de la Tourette syndrome	0.00406	0.0721	CbGeAlD
Amphetamine—CARTPT—central nervous system—Gilles de la Tourette syndrome	0.00406	0.0721	CbGeAlD
Amphetamine—DRD2—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00369	0.0534	CbGpPWpGaD
Amphetamine—DRD2—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00358	0.0518	CbGpPWpGaD
Amphetamine—CARTPT—brain—Gilles de la Tourette syndrome	0.00322	0.0572	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00312	0.0452	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00303	0.0439	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00294	0.0425	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00285	0.0413	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00283	0.0409	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00266	0.0385	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00245	0.0354	CbGpPWpGaD
Amphetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00244	0.0353	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00237	0.0344	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00221	0.032	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00186	0.0269	CbGpPWpGaD
Amphetamine—SLC18A2—midbrain—Gilles de la Tourette syndrome	0.00174	0.0309	CbGeAlD
Amphetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00169	0.0245	CbGpPWpGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00169	0.0245	CbGpPWpGaD
Amphetamine—MAOB—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00168	0.0244	CbGpPWpGaD
Amphetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00164	0.0237	CbGpPWpGaD
Amphetamine—SLC18A2—nervous system—Gilles de la Tourette syndrome	0.00143	0.0254	CbGeAlD
Amphetamine—SLC18A2—central nervous system—Gilles de la Tourette syndrome	0.00138	0.0245	CbGeAlD
Amphetamine—Diethylpropion—SLC6A3—Gilles de la Tourette syndrome	0.00136	0.231	CrCbGaD
Amphetamine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00132	0.0234	CbGeAlD
Amphetamine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00126	0.0182	CbGpPWpGaD
Amphetamine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00121	0.0215	CbGeAlD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00117	0.0169	CbGpPWpGaD
Amphetamine—MAOB—midbrain—Gilles de la Tourette syndrome	0.00115	0.0204	CbGeAlD
Amphetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00114	0.0165	CbGpPWpGaD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00114	0.0164	CbGpPWpGaD
Amphetamine—SLC18A2—brain—Gilles de la Tourette syndrome	0.00109	0.0194	CbGeAlD
Amphetamine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00108	0.0192	CbGeAlD
Amphetamine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00108	0.0156	CbGpPWpGaD
Amphetamine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00104	0.0185	CbGeAlD
Amphetamine—Lisdexamfetamine—SLC6A3—Gilles de la Tourette syndrome	0.00103	0.175	CrCbGaD
Amphetamine—SLC22A3—nervous system—Gilles de la Tourette syndrome	0.00102	0.0181	CbGeAlD
Amphetamine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.000993	0.0176	CbGeAlD
Amphetamine—SLC22A3—central nervous system—Gilles de la Tourette syndrome	0.000982	0.0174	CbGeAlD
Amphetamine—CYP2A6—brain—Gilles de la Tourette syndrome	0.000978	0.0174	CbGeAlD
Amphetamine—DRD2—midbrain—Gilles de la Tourette syndrome	0.000969	0.0172	CbGeAlD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000956	0.0138	CbGpPWpGaD
Amphetamine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000956	0.017	CbGeAlD
Amphetamine—MAOB—nervous system—Gilles de la Tourette syndrome	0.000944	0.0168	CbGeAlD
Amphetamine—MAOB—central nervous system—Gilles de la Tourette syndrome	0.000909	0.0161	CbGeAlD
Amphetamine—SLC22A5—midbrain—Gilles de la Tourette syndrome	0.000902	0.016	CbGeAlD
Amphetamine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000874	0.0155	CbGeAlD
Amphetamine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000842	0.0149	CbGeAlD
Amphetamine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000828	0.0147	CbGeAlD
Amphetamine—DRD2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000815	0.0118	CbGpPWpGaD
Amphetamine—DRD2—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.000811	0.0117	CbGpPWpGaD
Amphetamine—DRD2—nervous system—Gilles de la Tourette syndrome	0.000797	0.0141	CbGeAlD
Amphetamine—DRD2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000792	0.0115	CbGpPWpGaD
Amphetamine—SLC22A3—brain—Gilles de la Tourette syndrome	0.00078	0.0138	CbGeAlD
Amphetamine—DRD2—central nervous system—Gilles de la Tourette syndrome	0.000767	0.0136	CbGeAlD
Amphetamine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000759	0.0135	CbGeAlD
Amphetamine—Phenylpropanolamine—SLC6A3—Gilles de la Tourette syndrome	0.000725	0.123	CrCbGaD
Amphetamine—MAOB—brain—Gilles de la Tourette syndrome	0.000722	0.0128	CbGeAlD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000686	0.00992	CbGpPWpGaD
Amphetamine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000668	0.0119	CbGeAlD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000665	0.00963	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000662	0.00958	CbGpPWpGaD
Amphetamine—Phentermine—SLC6A3—Gilles de la Tourette syndrome	0.000646	0.109	CrCbGaD
Amphetamine—Dextroamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000616	0.104	CrCbGaD
Amphetamine—Pseudoephedrine—SLC6A3—Gilles de la Tourette syndrome	0.000613	0.104	CrCbGaD
Amphetamine—DRD2—brain—Gilles de la Tourette syndrome	0.000609	0.0108	CbGeAlD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000578	0.00837	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000572	0.00828	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00057	0.00825	CbGpPWpGaD
Amphetamine—SLC22A5—brain—Gilles de la Tourette syndrome	0.000567	0.0101	CbGeAlD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000561	0.00812	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000523	0.00757	CbGpPWpGaD
Amphetamine—DRD2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000517	0.00747	CbGpPWpGaD
Amphetamine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000479	0.0085	CbGeAlD
Amphetamine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000461	0.00818	CbGeAlD
Amphetamine—Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.00046	0.0779	CrCbGaD
Amphetamine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000457	0.0772	CrCbGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000445	0.00644	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00044	0.00637	CbGpPWpGaD
Amphetamine—DRD2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000434	0.00628	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000427	0.00618	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000398	0.00576	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000373	0.0054	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000371	0.00537	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000366	0.0053	CbGpPWpGaD
Amphetamine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000366	0.0065	CbGeAlD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000321	0.00465	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000314	0.00455	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000305	0.00441	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000301	0.00435	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000284	0.00411	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000284	0.00411	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000279	0.00404	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00026	0.00376	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000259	0.00375	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000249	0.0036	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000244	0.00353	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000242	0.0035	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000238	0.00344	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000226	0.00327	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000225	0.00326	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000219	0.00317	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HDC—Gilles de la Tourette syndrome	0.00021	0.00304	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000204	0.00296	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000202	0.00293	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000192	0.00278	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000187	0.0027	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HDC—Gilles de la Tourette syndrome	0.000178	0.00257	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00017	0.00245	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000165	0.00238	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000158	0.00228	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000157	0.00228	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000153	0.00221	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000153	0.00221	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000143	0.00207	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000135	0.00195	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000133	0.00193	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000132	0.00191	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000132	0.00191	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000131	0.00189	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00013	0.00188	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000121	0.00175	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000103	0.00149	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000103	0.00149	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000102	0.00148	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.97e-05	0.00144	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.97e-05	0.00144	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.54e-05	0.00124	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	8.45e-05	0.00122	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.5e-05	0.000941	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.8e-05	0.00084	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.74e-05	0.000831	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.63e-05	0.000815	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.27e-05	0.000763	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.12e-05	0.00074	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.68e-05	0.000532	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.34e-05	0.000483	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.11e-05	0.00045	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.02e-05	0.000437	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.97e-05	0.000285	CbGpPWpGaD
